Clinical Trial

Pilot Study Assessing the Feasibility and Impact of a Remote Adapted Physical Activity Program on Quality of Life in Patients With Inflammatory Bowel Disease (IBD)

Study acronym: APIMICI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 24, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity. Emerging evidence suggests that light to moderate physical activity may help reduce systemic and intestinal inflammation and improve IBD-related outcomes. However, access to structured physical activity programs remains limited, and personal or professional constraints may hinder participation. This pilot study aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity (APA) program on the quality of life of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. This study evaluates the effects of a 12-weeks remote APA intervention on quality of life as the primary outcome. Secondary objectives include assessing changes in anxiety and depression, fatigue levels, IBD activity, and smoking behavior. The findings from this study may inform the development of scalable, non-pharmacological strategies to support symptom management and well-being in individuals with IBD.
Trial Details
NCT Number NCT07191106
Lead Sponsor Raincy Montfermeil Hospital Group
Collaborators: Janssen Cilag S.A.S.
Conditions Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Enrollment 72 participants
Start Date 2025-09-15
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-24